Back to News
Market Impact: 0.3
Nicox Partner Ocumension's NCX 470 NDA Accepted For Review In China For Glaucoma
Source: Nasdaq
Healthcare & BiotechProduct LaunchesRegulation & Legislation
Nicox announced that China’s NMPA accepted the New Drug Application for NCX 470 for review, following submission by its exclusive China licensee Ocumension Therapeutics. The acceptance advances NCX 470 through the Chinese regulatory pathway, but approval timing and commercial impact remain uncertain.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
mildly positive
Sentiment Score
0.35
Ticker Sentiment
ALCOX0.55
More News
- Apple says it will replace iPhone Duo units showing screen problems
- USTR Greer tells EU that loan to Airbus threatens trade truce on aircraft financing
- Anthropic’s risk factors include the end of humanity, a feud with the Pentagon, and CEO Dario Amodei’s reputation
- Iran’s anti-negotiation hardliners turn against President Pezeshkian
- J&J's potential 'game-changer' drug — plus, what Microsoft's mass buyouts mean
- Apple responds to user reports of broken iPhone Duo screens on new foldable phone